Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | GPR139 | Q6DWJ6 | 5/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249378 | 1.00 | IDH1 (0.36) | IDH1BRD4LMNATAAR1HDAC1 | |
| SCHEMBL14429779 | 1.00 | IDH1 (0.36) | IDH1BRD4LMNATAAR1HDAC1 | |
| SCHEMBL14429777 | 1.00 | IDH1 (0.36) | IDH1BRD4LMNATAAR1HDAC1 | |
| SCHEMBL10249354 | 1.00 | IDH1 (0.36) | IDH1BRD4LMNATAAR1HDAC1 | |
| SCHEMBL1606487 | 0.87 | MAPKAPK2 (0.41) | IDH1 | |
| SCHEMBL14429454 | 0.87 | IDH1 (0.37) | IDH1LMNAPOLB | |
| SCHEMBL1606410 | 0.87 | MAPKAPK2 (0.41) | IDH1 | |
| SCHEMBL1605418 | 0.87 | TAAR1 (0.46) | IDH1LMNATAAR1HDAC1POLB | |
| SCHEMBL1605556 | 0.87 | TAAR1 (0.46) | IDH1LMNATAAR1HDAC1POLB | |
| SCHEMBL5454033 | 0.84 | IDH1 (0.40) | IDH1GPR139TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2012-01-12 | — | — | US | disclosed |
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | IDH1 188/4885BRD4 3543/4885LMNA 1410/4885 |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | IDH1 188/4885BRD4 3543/4885LMNA 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.